The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10481 malaria professionals are enjoying the free benefits of MalariaWorld today


Randomized double-blind controlled Phase I/IIa trial to assess the efficacy of malaria vaccine PfCS102 to protect against challenge with P. falciparum

September 14, 2010 - 12:34 -- Patrick Sampao
Blaise G., Valérie D., et al.
Vaccine, Volume 28, Issue 40, 14 September 2010, Pages 6573-6580

The aim of this Phase I/IIa double-blind controlled trial was to test the efficacy of the sporozoite-based malaria vaccine PfCS 282–383 (PfCS102) to protect against Plasmodium falciparum parasitaemia.

Medical Condition: 
Medical Treatment: 
Subscribe to RSS - PfCS102